Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in ...

First-in-human study evaluates safety, pharmacokinetics, biomarker analyses, target engagement, and anti-tumor activity in ...

As spine leaders look ahead to 2026, enthusiasm around regenerative medicine and neuromodulation continues to build. But much of the conversation still flattens a field that is far more complex than ...

As people with α-gal syndrome seek to boost awareness, researchers are looking to harness the molecule for new therapies ...

Researchers have identified a single protein whose absence can cripple tumors in mice, slowing their growth and in some cases ...

Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical ...

Report analyzes publicly available category information, company-stated product details, and consumer search patterns as ...

Increasing longevity is forcing a rethink of public policy, individual lifestyles, and private finances. Yet it is crucial not to overreact or grow unduly alarmed about shifting population dynamics.

“This work is unique in its scale of assessment of food additives in a large number of study participants, and also puts added focus on the recognition by the International Agency for Research on ...

Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 - -- Expects to initiate global Phase 1/2 MAD clinical study ...

Portable chargers are supposed to be the quiet workhorses in your bag, not a source of fire risk on your desk or nightstand.